Amarin Corp Plc (AMRN)

[kvenne]

sts66,

The Matina's patent states the following:

The present invention provides a pharmaceutical composition comprising eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA), wherein the amount of EPA and DPA is about 55% or more by weight of the total amount of fatty acids, and wherein the ratio of DHA:DPA is no more than 1:1. The present invention also provides a pharmaceutical composition comprising eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA), wherein the amount of EPA and DPA is about 55% or more by weight of the total amount of fatty acids, and wherein the ratio of DHA:DPA is no more than 1:1.

So there mix is EPA, DHA, and DPA sames as what Epanova has a patent for in the OB. So I have to agree with this guy that they get no NME or NCE. However perhaps they are not concerned with this as DPA is in short supply and they are the only ones with a propriety method that can synthesize it? What does this cost?

I would also agree with him that they would have to run there own CVOT since DPA is something new to the mix. I mean if Lovaza ran a CVOT and it was successful do you think Vascepa as EPA only could have piggy backed off of it.

I believe you are right it was discussed on this board on how we have Epanova locked out and I think I remember it is on the raising LDL-C 20% or more, but that would not hold true for MAT-90001.